One Health… One Drug… One Disease Model

The coronavirus pandemic and recent viral outbreaks challenges us to rethink the control of viral agents. Emerging pathogens such as SARS-1, MERS CoV, Ebola, Zika, Avian Influenza, and Chikungunya viruses, etc. are becoming ever-increasing threats. The coronavirus pandemic clearly exposed vulnerabilities on a global scale to infectious organisms for which efficacious treatments were not available. While many drugs exist for treating bacterial infections, fewer FDA-approved antiviral drugs exist for the human market, and none are FDA-approved for the veterinary market.

CYGNOS Biotech embraces the ‘One Health’ strategy for product development. The ‘One Health’ paradigm is a global strategy for promoting comprehensive interdisciplinary collaborations and communications in all aspects of health care for humans, animals and the environment. This paradigm recognizes that attaining optimal human health outcomes is intimately connected to the health of animals influenced by climate change. It is an integrative effort of multiple disciplines working locally, nationally, and worldwide.

The CYGNOS product discovery approach is designed to support veterinary translational clinical research to explore potential human applications. This could significantly reduce the time required for FDA claims approval. Thus, the ‘One Health… One Drug… One Disease Model’.

With the devastating outcome of COVID-19 and other similar viral epidemics, the CYGNOS ‘One Health’ approach to deal with Zoonotic Diseases should be a call for all stakeholders to support our project through partnership and financial support.